Evidence map›Paper›PMID 41002890›Full record

ArticleMembranes2025

Characterization of TMEM16F-Specific Affibodies and Their Cellular Effects.

Eunyoung Kim, Jinho Bang, Sunghyun Kim, Byoung-Cheol Lee

Abstract read
In one paragraph

Article in Membranes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eunyoung KimNeurovascular Unit Research Group, Korea Brain Research Institute, Daegu 41068, Republic of Korea.
Jinho BangBio-Healthcare Materials Center, Korea Institute of Ceramic Engineering and Technology, Cheongju 28160, Republic of Korea.
Sunghyun KimBio-Healthcare Materials Center, Korea Institute of Ceramic Engineering and Technology, Cheongju 28160, Republic of Korea.
Byoung-Cheol LeeNeurovascular Unit Research Group, Korea Brain Research Institute, Daegu 41068, Republic of Korea.

Funding

KBRI basic research program through Korea Brain Research Institute funded by Ministry of Sci-ence and ICT 25-BR-01-02Korea Institute of Ceramic Engineering and Technology KICET 2410002182National Research Foundation (NRF) of Korea funded by the Ministry of Science and ICT (MIST) of the Republic of Korea 2022R1F1A1071221National Research Foundation (NRF) of Korea funded by the Ministry of Science and ICT (MIST) of the Republic of Korea RS-2023-00246123
6 · The paper itself

Abstract

The TMEM16 (Anoctamin) family comprises a group of transmembrane proteins involved in diverse physiological processes, including ion transport and phospholipid scrambling. TMEM16F (Anoctamin 6), a phospholipid scramblase and nonselective ion channel, plays a central role in membrane remodeling, blood coagulation, immune responses, and cell death pathways through its ability to externalize phosphatidylserine in response to elevated intracellular calcium levels. Consequently, modulating TMEM16F activity has emerged as a promising strategy for the development of new therapeutic applications. Despite the functional importance of TMEM16F, TMEM16F modulators have received little study. In a previous study, we generated TMEM16F-specific affibodies by biopanning a phage display library for affibodies that bind to brain-specific TMEM16F (hTMEM16F) variant 1. In this study, we selected six other affibodies from among the 38 previously sequenced affibody candidates and characterized them. After purification, we confirmed that two of these affibodies bound to human TMEM16F with high affinity. To provide functional insights into how these affibodies modulate TMEM16F activity, we tested whether they could exert functional effects at the cellular level. Finally, we show that TMEM16F affibody attenuated the neuronal cell death induced by glutamate and microglial phagocytosis, suggesting that these affibodies might have potential therapeutic and diagnostic applications.

Indexed as

affibodybiopanningchannelscramblaseTMEM16

Identifiers

PMID41002890
PMCPMC12471793

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.